The clinical significance of CXCL16 in the treatment of advanced non‐small cell lung cancer

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)‐A, has shown efficacy in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). There are no identified or clinically validated biomarkers to determine the efficacy of bevacizumab. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Yuji, Kobayashi, Nobuaki, Sato, Takashi, Nakashima, Kentaro, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180569/
https://www.ncbi.nlm.nih.gov/pubmed/32163231
http://dx.doi.org/10.1111/1759-7714.13387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180569/
https://www.ncbi.nlm.nih.gov/pubmed/32163231
http://dx.doi.org/10.1111/1759-7714.13387

Ejemplares similares